{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"4"},{"groupId":"OG011","value":"5"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"3"},{"groupId":"OG019","value":"3"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"5"},{"groupId":"OG022","value":"5"},{"groupId":"OG023","value":"3"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"1"},{"groupId":"OG026","value":"1"},{"groupId":"OG027","value":"3"},{"groupId":"OG028","value":"3"},{"groupId":"OG029","value":"3"},{"groupId":"OG030","value":"3"},{"groupId":"OG031","value":"6"},{"groupId":"OG032","value":"4"},{"groupId":"OG033","value":"6"},{"groupId":"OG034","value":"8"},{"groupId":"OG035","value":"9"}],"title":"Very easy to swallow tablet"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"4"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"3"},{"groupId":"OG012","value":"1"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"1"},{"groupId":"OG020","value":"2"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"1"},{"groupId":"OG023","value":"1"},{"groupId":"OG024","value":"1"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"},{"groupId":"OG029","value":"0"},{"groupId":"OG030","value":"2"},{"groupId":"OG031","value":"0"},{"groupId":"OG032","value":"0"},{"groupId":"OG033","value":"1"},{"groupId":"OG034","value":"0"},{"groupId":"OG035","value":"0"}],"title":"Easy to swallow tablet"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"1"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"1"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"1"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"},{"groupId":"OG029","value":"0"},{"groupId":"OG030","value":"1"},{"groupId":"OG031","value":"1"},{"groupId":"OG032","value":"0"},{"groupId":"OG033","value":"1"},{"groupId":"OG034","value":"1"},{"groupId":"OG035","value":"0"}],"title":"Neither easy nor difficult to swallow tablet"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"1"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"},{"groupId":"OG029","value":"0"},{"groupId":"OG030","value":"0"},{"groupId":"OG031","value":"0"},{"groupId":"OG032","value":"0"},{"groupId":"OG033","value":"0"},{"groupId":"OG034","value":"0"},{"groupId":"OG035","value":"0"}],"title":"Difficult to swallow tablet"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"},{"groupId":"OG026","value":"0"},{"groupId":"OG027","value":"0"},{"groupId":"OG028","value":"0"},{"groupId":"OG029","value":"0"},{"groupId":"OG030","value":"0"},{"groupId":"OG031","value":"0"},{"groupId":"OG032","value":"0"},{"groupId":"OG033","value":"1"},{"groupId":"OG034","value":"0"},{"groupId":"OG035","value":"0"}],"title":"Very difficult to swallow tablet"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"7"},{"groupId":"OG009","value":"10"},{"groupId":"OG010","value":"8"},{"groupId":"OG011","value":"8"},{"groupId":"OG012","value":"2"},{"groupId":"OG013","value":"1"},{"groupId":"OG014","value":"1"},{"groupId":"OG015","value":"2"},{"groupId":"OG016","value":"1"},{"groupId":"OG017","value":"2"},{"groupId":"OG018","value":"5"},{"groupId":"OG019","value":"4"},{"groupId":"OG020","value":"4"},{"groupId":"OG021","value":"6"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"6"},{"groupId":"OG024","value":"1"},{"groupId":"OG025","value":"1"},{"groupId":"OG026","value":"1"},{"groupId":"OG027","value":"3"},{"groupId":"OG028","value":"3"},{"groupId":"OG029","value":"3"},{"groupId":"OG030","value":"6"},{"groupId":"OG031","value":"7"},{"groupId":"OG032","value":"4"},{"groupId":"OG033","value":"9"},{"groupId":"OG034","value":"9"},{"groupId":"OG035","value":"9"}],"units":"Participants"}],"description":"Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) by asking a question - \" Was it easy or difficult for the study subject to swallow the abemaciclib today?\" Participants or their caregivers or both could respond using the following possible answers: Very difficult, difficult, neither easy nor difficult, easy, or very easy.","groups":[{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG000","title":"Part A Cohort A1 (Caregiver Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG001","title":"Part A Cohort A1 (Caregiver Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG002","title":"Part A Cohort A1 (Caregiver Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG003","title":"Part A Cohort A1 (Participant Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG004","title":"Part A Cohort A1 (Participant Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 70 milligrams per meters squared (mg/m²), administered orally twice daily (BID).\n* Irinotecan: 50 mg/m²/day, administered intravenously (IV) on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG005","title":"Part A Cohort A1 (Participant Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG006","title":"Part A Cohort A-1(Caregiver Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG007","title":"Part A Cohort A-1(Caregiver Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG008","title":"Part A Cohort A-1(Caregiver Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG009","title":"Part A Cohort A-1(Participant Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG010","title":"Part A Cohort A-1(Participant Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 55 mg/m², administered orally BID.\n* Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG011","title":"Part A Cohort A-1(Participant Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG012","title":"Part B Cohort B1 (Caregiver Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG013","title":"Part B Cohort B1 (Caregiver Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG014","title":"Part B Cohort B1 (Caregiver Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG015","title":"Part B Cohort B1 (Participant Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG016","title":"Part B Cohort B1 (Participant Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 70 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG017","title":"Part B Cohort B1 (Participant Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG018","title":"Part B Cohort B2 (Caregiver Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG019","title":"Part B Cohort B2 (Caregiver Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG020","title":"Part B Cohort B2 (Caregiver Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG021","title":"Part B Cohort B2 (Participant Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG022","title":"Part B Cohort B2 (Participant Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 90 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG023","title":"Part B Cohort B2 (Participant Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG024","title":"Part B Cohort B3 (Caregiver Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG025","title":"Part B Cohort B3 (Caregiver Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG026","title":"Part B Cohort B3 (Caregiver Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG027","title":"Part B Cohort B3 (Participant Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG028","title":"Part B Cohort B3 (Participant Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG029","title":"Part B Cohort B3 (Participant Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG030","title":"Part B Cohort B5 (Caregiver Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG031","title":"Part B Cohort B5 (Caregiver Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG032","title":"Part B Cohort B5 (Caregiver Responses - Cycle 2 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG033","title":"Part B Cohort B5 (Participant Responses - Cycle 1 Day 1)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG034","title":"Part B Cohort B5 (Participant Responses - Cycle 1 Day 15)"},{"description":"Participants received:\n\n* Abemaciclib: 115 mg/m², administered orally BID.\n* Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle.\n\nTreatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.","id":"OG035","title":"Part B Cohort B5 (Participant Responses - Cycle 2 Day 1)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants in Parts A and B, who received at least one dose of abemaciclib and had evaluable data for this outcome. Per protocol, data were summarized by responses provided by participants, and/or caregivers on the acceptability of the abemaciclib received on Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (21 Day Cycles)","title":"Abemaciclib Tablet Acceptability","type":"SECONDARY","unitOfMeasure":"Participants"}